B2M and neoplasm: Consistent with the in vitro cell proliferation assays (Figure 2, H and I), MALT1 KO greatly suppressed tumor growth and serum levels of β-2-microglobulin (B2M), a systematic indicator of tumor load, in both JeKo-1 (P < 0.0001 and P < 0.05, respectively) and JeKo BTK KD-2 CDX (P < 0.001 and P < 0.0001, respectively) models, while CARD11 KO suppressed tumor growth and serum levels of B2M in only the JeKo-1 CDX model 1 (P < 0.0001 and P < 0.05, respectively) (Figure 2, J–N).